Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intezyne Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10554
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-specific release mechanisms. Intezyne’s pipeline products include IT-139, IT-141 and IT-147. The company’s IT-141 is a formulation of SN-38 encapsulated using its nanoparticle drug delivery platform. It has active preclinical research programs for delivery of DNA and siRNA, molecularly targeted drugs and orally delivered IVECT therapeutics. Intezyne is headquartered in Tampa, Florida, the US.

Intezyne Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intezyne Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intezyne Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intezyne Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intezyne Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Intezyne Technologies Raises USD10 Million in Series A Preferred Financing 11
Partnerships 12
Exosome Diagnostics Enters into Agreement with Intezyne 12
Acquisition 13
Intezyne Technologies Acquires Niiki Pharma 13
Intezyne Inc – Key Competitors 15
Intezyne Inc – Key Employees 16
Intezyne Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Mar 15, 2018: Intezyne Taps Veteran Banker E. Russell McAllister as President and CEO 18
Product News 19
04/13/2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting 19
03/31/2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium 20
03/22/2018: Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting 21
Product Approvals 22
Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer 22
Clinical Trials 23
Apr 16, 2018: Intezyne To Showcase Novel Cancer Resistance Pathway Inhibitor IT-139′S Potential In Gastric Cancer At ChinaBio Partnering Forum 2018 In Suzhou, PRC 23
Apr 10, 2018: Combination of Checkpoint Inhibitors and Intezyne’s Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Intezyne Inc, Pharmaceuticals & Healthcare, Key Facts 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intezyne Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intezyne Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intezyne Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intezyne Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intezyne Technologies Raises USD10 Million in Series A Preferred Financing 11
Exosome Diagnostics Enters into Agreement with Intezyne 12
Intezyne Technologies Acquires Niiki Pharma 13
Intezyne Inc, Key Competitors 15
Intezyne Inc, Key Employees 16

List of Figures
Intezyne Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intezyne Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intezyne Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Svenska Cellulosa Aktiebolaget:企業の戦略・SWOT・財務情報
    Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report Summary Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Advanced Accelerator Applications SA (AAAP):企業の財務・戦略的SWOT分析
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Veran Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Veran Medical Technologies Inc (Veran) is a medical device company that develops products for minimally invasive delivery of interventional oncology therapies. The company provides endobronchial products such as SpiN thoracic navigation system, Always-On tip tracked instruments, SpiNPerc and …
  • Orexigen Therapeutics Inc (OREX)-製薬・医療分野:企業M&A・提携分析
    Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased …
  • QAD Inc (QADA):企業の財務・戦略的SWOT分析
    QAD Inc (QADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Global Marine Systems Ltd:企業の戦略的SWOT分析
    Global Marine Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Mizuno Corporation (8022):企業の財務・戦略的SWOT分析
    Mizuno Corporation (8022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Arkray Inc:企業の製品パイプライン分析2018
    Summary Arkray Inc (Arkray), formerly KDK Corp is a medical device company that offers diagnostic products. The company offers diagnostic products and equipments for diabetes diagnosis and urinalysis applications. Its products comprise automatic glycohemoglobin analyzer for diabetes, automated analy …
  • GE Healthcare LLC-製薬・医療分野:企業M&A・提携分析
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    FieldPoint Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary FieldPoint Petroleum Corp (FieldPoint) is an oil and gas company that acquires, operates and develops oil and gas properties. The company’s acquisition includes leasehold and working intere …
  • Novacyt SA (ALNOV):企業の財務・戦略的SWOT分析
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …
  • 23andMe Inc-医療機器分野:企業M&A・提携分析
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. It offers clinical development, research and development, ancestry services, commercialization …
  • Second Sight Medical Products Inc (EYES):企業の財務・戦略的SWOT分析
    Summary Second Sight Medical Products Inc (Second Sight) is a medical device company that develops, manufactures and markets implantable visual prosthetics for blind individuals. The company offers Argus II retinal prosthesis system, a device that restores some functional vision for people suffering …
  • AirAsia Berhad:企業のM&A・事業提携・投資動向
    AirAsia Berhad - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AirAsia Berhad Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Inditex SA (ITX):企業の財務・戦略的SWOT分析
    Inditex SA (ITX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Calithera Biosciences Inc (CALA):企業の財務・戦略的SWOT分析
    Summary Calithera Biosciences Inc (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer . The company’s product pipeline includes CB-839, a glutamina …
  • Sumitomo Electric Industries, Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Electric Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Electric Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Aerovironment Inc:企業の戦略・SWOT・財務分析
    Aerovironment Inc - Strategy, SWOT and Corporate Finance Report Summary Aerovironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • AGL Energy Ltd (AGL):企業の財務・戦略的SWOT分析
    AGL Energy Ltd (AGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Harman International Industries Inc:企業の戦略的SWOT分析
    Harman International Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆